Glaxosmithkline Biologicals Sa

Glaxosmithkline LLC

Cindy Castado

Jan Poolman

Normand Blais

Marianne Dewerchin

Patrick Chomez

Julien Thierry Massaux

Philippe Denoel

Vincent Weynants

Patrick Rheault

Steve Labbe

Sandra Giannini

Wivine Burny

Nicolas Pierre Lecrenier

Nathalie Isabelle Devos

Nicolas Pierre Fernand Lecrenier

Cecile Anne Neyt

Fabrice Godfroid

Ceclie Anne Neyt

Nicolas Piere Fernand Lecrenier

The present invention relates to nucleic acid constructs capable of encoding antigenic peptides or polypeptides derived from multiple Human Papilloma Virus (HPV) early proteins, and to immunogenic compositions comprising such nucleic acid constructs and a pharmaceutically acceptable carrier. Such nucleic acid constructs and immunogenic compositions are useful in the treatment of persistent HPV infection and low-grade HPV lesions, particularly infections and lesions of human anogenital epithelial tissue, such as cervical epithelia.

Compositions and methods of treatment

Nucleotide constructs encoding antigenic peptides or polypeptides derived from multiple Human Papilloma Virus (HPV) early proteins, immunogenic compositions comprising such constructs and a pharmaceutically acceptable carrier, and uses thereof.

Viral antigens

The present invention relates to compositions comprising() Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.

UspA2 protein constructs and uses thereof

The present application relates to immunogenic compositions comprising a mixture of staphylococcal antigens which combines antigen having different functions, for instance, combinations including a staphylococcal extracellular component binding protein and a staphylococcal transporter protein or a staphylococcal extracellular component binding protein and a staphylococcal regulator of virulence or toxin or a staphylococcal transporter protein and a staphylococcal regulator of virulence or toxin. Vaccines, methods of treatment, uses of and processes to make a staphylococcal vaccine are also described.

Immunogenic composition for use in vaccination against staphylococci

Polynucleotides encoding fusion proteins comprising fragments of toxin A and toxin B fromare described, as well as vectors and host cells containing such polynucleotides.

Nucleotide sequences, vectors and host cells

The present invention relates to fusion proteins comprising fragments from toxin A and/or toxin B of, wherein the polypeptide elicits antibodies that neutralize toxin A or toxin B or both.

The present invention relates to immunogenic compositions comprising isolatedCDTb and/or CDTa protein. In particular the isolatedCDTb protein is suitably a truncated CDTb protein comprising the receptor binding domain or a mutated CDTb protein incapable of binding to CDTa, and the isolatedCDTa protein is suitably a truncated CDTa protein which does not comprise the C-terminal domain. In particular the invention also relates to fusion proteins comprising a CDTa protein and a CDTb protein and also fusion proteins between an isolatedtoxin A protein and/or an isolatedtoxin B protein fused to a CDTb protein.

Immunogenic composition comprising elements of C. difficile CDTb and/or CDTa proteins

Compositions for the treatment or prevention of Neisserial infection and methods for their use and manufacture are provided herein.

Immunogenic composition

The present invention relates to fusion proteins comprising fragments of toxin A and toxin B from, such as wherein the first fragment and the second fragment are adjacent to one another and wherein the first repeat portion and the second repeat portion have sequence similarity to one another.

The invention provides BASB232 polypeptides and polynucleotides encoding BASB232 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. The invention further provides immunogenic compositions comprising a plurality of antigens selected from at least two different categories of antigen, having different functions within. Examples of such categories of antigen are autotransporter proteins, iron acquisition proteins, lipoproteins, adhesins and toxins/invasins.

Growing community of inventors

Rixensart, Belgium

Cindy Castado